Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

npj Breast Cancer (3)
Nature Medicine (3)
Blood Cancer Journal (1)
Nature (1)
Nature Cancer (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (7)
Amendments and Corrections (2)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Diseases
Health care
Immunology
Medical research
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–9 of 9 results

Advanced filters: Author: Sara Balduzzi Clear advanced filters

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers

The results from the phase II NICHE trial on immunotherapy in mismatch-proficient colon cancer are presented.

Pedro B. Tan
Yara L. Verschoor
Myriam Chalabi
ResearchOpen Access20 Oct 2025
Nature

Volume: 648, P: 726-735
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

In the phase 2 NICHE-3 trial, patients with locally advanced mismatch repair-deficient colon cancer who were treated with neoadjuvant anti-PD1 and anti-LAG3 agents showed high rates of pathological responses, requiring validation in larger trials.

Peter G. M. de Gooyer
Yara L. Verschoor
Myriam Chalabi
ResearchOpen Access15 Sept 2024
Nature Medicine

Volume: 30, P: 3284-3290
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

A neoadjuvant treatment regimen of anti-PD-L1 monotherapy followed by anti-PD-L1 plus chemotherapy was well tolerated and led to a major pathologic response rate of 70% in patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Yara L. Verschoor
Joris van de Haar
Myriam Chalabi
ResearchOpen Access08 Jan 2024
Nature Medicine

Volume: 30, P: 519-530
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation

Federico Lussana
Chiara F. Magnani
Andrea Biondi
ResearchOpen Access03 Apr 2025
Blood Cancer Journal

Volume: 15, P: 1-14
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

Voorwerk et al. report the clinical and translational results from a phase II trial evaluating the combination of carboplatin with anti-PD-L1 in patients with invasive lobular breast cancer, who have been underrepresented in clinical trials so far.

Leonie Voorwerk
Olga I. Isaeva
Marleen Kok
ResearchOpen Access10 Apr 2023
Nature Cancer

Volume: 4, P: 535-549
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Yara L. Verschoor
Joris van de Haar
Myriam Chalabi
Amendments and CorrectionsOpen Access06 Mar 2024
Nature Medicine

Volume: 30, P: 1499
Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Maria Vittoria Dieci
Giancarlo Bisagni
Valentina Guarneri
Amendments and CorrectionsOpen Access12 Apr 2023
npj Breast Cancer

Volume: 9, P: 1
Immune landscape of breast tumors with low and intermediate estrogen receptor expression

Leonie Voorwerk
Joyce Sanders
Marleen Kok
ResearchOpen Access13 May 2023
npj Breast Cancer

Volume: 9, P: 1-10
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial

Maria Vittoria Dieci
Giancarlo Bisagni
Valentina Guarneri
ResearchOpen Access04 Feb 2023
npj Breast Cancer

Volume: 9, P: 1-7